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The first successful pancreas transplantation in conjunction with a simultaneous kidney transplantation was performed
in 1966 by Kelly, Lillehei and others from the University of Minnesota. In Taipei Veterans General Hospital, the first pan-
creas transplantation (simultaneously coupled with kidney transplantation) was successfully performed on September
19, 2003, and we were qualified to harvest and transplant pancreas graft by the Taiwan Department of Health on August
31, 2007. Currently, pancreas transplantation remains the most effective method of establishing physiological and durable
normoglycemia for patients with diabetes mellitus. The main indication for pancreas transplantation is type 1 diabetes
with diabetic complications such as nephropathy, retinopathy, neuropathy and cardiocerebral vasculopathy, or with fre-
quent life-threatening hypoglycemia or hyperglycemia. Pancreas graft survival rate at 1 year was 85% for simultaneous
pancreas-kidney transplantation, 78% for pancreas-after-kidney transplantation, and 76% for pancreas transplantation
alone. At 3 years, pancreas graft survival rates were at least 62% in all categories. [J Chin Med Assoc 2009;72(1):4–9]
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History of Pancreas Transplantation
The first successful pancreas transplantation in con-
junction with a simultaneous kidney transplantation
was performed by Richard Lillehei et al, from the
University of Minnesota, in 1966, 3 years after the
first kidney transplantation.1 A pancreas along with
duodenum was transplanted into a 28-year-old woman
and her blood sugar levels decreased immediately after
transplantation, but she died of pulmonary embolism
3 months later. In 1979, the first living-related partial
pancreas transplantation was done. Until about 1990,
the procedure was considered experimental. After ani-
mal study done in Taipei Veterans General Hospital,2
the first pancreas transplantation (simultaneously cou-
pled with kidney transplantation) was successfully per-
formed on September 19, 2003, and we were qualified
to harvest and transplant pancreas graft by the Taiwan
Department of Health on August 31, 2007. At pres-
ent, about 1,600–1,800 pancreas transplantations are
performed annually in the United States, according to
the United Network for Organ Sharing (UNOS) and
the International Pancreas Transplantation Registry
(IPTR). To date, more than 25,000 pancreas trans-
plants have been performed, mainly in the United
States.3–6 Currently, pancreas transplantation remains
the most effective method of establishing physiological
and durable normoglycemia for patients with diabetes
mellitus (DM).
Classification of Pancreas
Transplantation
Traditionally, pancreas transplantations were catego-
rized into 3 types. Table 1 shows a comparison of the
3 types of pancreas transplantations.7–12
1. Simultaneous pancreas-kidney transplantation (SPK)
is when the pancreas and kidney are transplanted
simultaneously from the same deceased donor.
About 75–80% of pancreas transplantations are SPK.
2. Pancreas-after-kidney transplantation (PAK) is when
a cadaveric or deceased donor pancreas transplan-
tation is performed after a previous, and different,
living or deceased donor kidney transplantation.
About 10–15% of pancreas transplantations are PAK.
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3. Pancreas transplantation alone (PTA) is for patients
with type 1 DM but adequate kidney function. The
remaining 5–10% of cases are PTA.
Indications and Contraindications for
Pancreas Transplantation
In patients with type 1 DM, the pancreas no longer
produces insulin due to autoimmune destruction of
pancreatic islets. In Western countries, the incidence
of type 1 DM is high, up to 10–15% of the diabetic
population. Currently, the prevalence of type 1 DM
in the United States is around 1,100,000 individuals,
with 35,000 new cases diagnosed each year. In Taiwan,
it is estimated that type 1 DM is about 1–3% of the
diabetic population; thus, there are about 6,000–8,000
patients with this disease. At the turn of the 20th cen-
tury, a patient diagnosed with type 1 DM had an aver-
age life expectancy of only 2 years. The development
of insulin as a therapeutic agent revolutionized the
treatment of DM by changing it from a rapidly fatal
disease to a chronic illness. Unfortunately, this in-
creased longevity allowed the development of second-
ary complications, including nephropathy, neuropathy,
retinopathy, and macrovascular and microvascular com-
plications, occurring 10–20 years after disease onset.
Currently, no practical mechanical insulin-delivery
method, coupled with an effective glucose-sensory de-
vice, can replace pancreatic insulin secretion well enough
to produce good physiologic control of blood sugar to
achieve a constant and near-euglycemic state without
the risk of hypoglycemia. The purposes of pancreas
transplantation are to produce complete insulin inde-
pendence, improve the quality and quantity of life,
and hopefully to ameliorate or reverse diabetes-related
complications. Therefore, it makes sense that pan-
creas transplantation in a patient with type 1 DM may
be able to cure their disease. Pancreas transplantation
is rarely indicated for type 2 DM because the major
problem there is not a failing pancreas, but the body’s
inability to respond to insulin in the right way.8–13
Pancreas transplantation is a life-enhancing, but
not a life-saving, procedure. In addition, the impact of
early and long-term exposure to immunosuppressants
on a young patient should be taken into consideration.
The following sections list the current indications 
and contraindications for pancreas transplantation in
Taiwan.
Indications for pancreas transplantation
• Type 1 DM or low serum peptide with diabetic
complications such as nephropathy, retinopathy,
neuropathy and cardiocerebral vasculopathy.
• Type 1 DM or low serum peptide with frequent
life-threatening hypoglycemia or hyperglycemia.
• Type 1 DM or low serum peptide with disability in
learning, working and life.
• Type 2 DM requiring insulin control, but < 1.5 U/
kg/day, and kidney transplantation.
Contraindications for pancreas transplantation
• Age > 65 years.
• Uncontrollable infection.
• Human immunodeficiency virus infection.
• Untreated tuberculosis.
• Malignancy, except for the following conditions:
– intraductal papillary mucinous neoplasm of the
pancreas, neuroendocrine tumor of the pancreas,
incidental renal carcinoma, in situ carcinoma
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Table 1. Classification and comparison of pancreas transplantation
Transplant type Advantages Disadvantages
Simultaneous One operation More advanced diabetic complications
pancreas-kidney Similar protocol in immunosuppressants
(SPK), 80% Easier to detect pancreas rejection early 
by monitoring kidney graft
Better outcome
Pancreas-after-kidney Already immunosuppressed Two operations
(PAK), 15% More advanced diabetic complications
More difficult to detect pancreas 
rejection early
Mediocre outcome
Pancreas transplantation Lower surgical risks with less or no Early exposure to immunosuppressants
alone (PTA), 5% diabetic complications More difficult to detect pancreas 
rejection early
Mediocre outcome
(excluding bladder), Dukes’ A colon cancer, basal
cell carcinoma;
– disease-free interval >5 years for malignant mela-
noma, breast cancer, gastrointestinal carcinoma,
lung cancer;
– disease-free interval >2 years for other malig-
nancies.
• Autoimmune disease treated with prednisolone
>10 mg/day or other immunosuppressants.
• Poor compliance, unresolvable psychosocial prob-
lems or severe psychiatric disorder.
• Major medical conditions prohibiting a major
operation.
• Uncorrectable severe cardiocerebrovascular or
peripheral vascular disorder preventing self-care.
• Drug or alcohol abuse.
Surgical Considerations
Currently, pancreas grafts are mainly from deceased
donors with brain death. Exclusion criteria for an
ideal pancreas donor include:
• age >55 years or < 5 years;
• history of diabetes (check HbA1c if DM history is
not available);
• history of chronic alcohol abuse, malignancy (except
skin or central nervous system), chronic infection,
recent intravenous drug abuse;
• prolonged episodes of hypotension;
• high-dose vasopressor use;
• acute systemic infection;
• documented pancreatitis.
Determining donor human leukocyte antigen typ-
ing, serologies, and pretransplant lymphocytotoxic
crossmatch results with patients on the pancreas trans-
plantation waiting list will permit the ideal situation
of allocating the cadaveric pancreas prior to organ
procurement. The cold ischemia time of the pancreas
prior to implantation should be minimized. Pancreas
grafts do not tolerate cold ischemia as well as kidney
grafts. Ideally, the pancreas should be revascularized
within 24 hours from the time of cross-clamping at
procurement.8–16
Surgical Techniques
The surgical techniques for pancreas transplantation
are diverse, and no standard methodology is used by
all programs. The native pancreas is not removed.
Pancreas Y-graft arterial reconstruction is prepared on
the back table, with anastomosis of the donor internal
iliac artery to the graft splenic artery, and the donor
external iliac artery to the graft superior mesenteric
artery. The arterial Y-graft of the pancreas is usually
anastomosed to the recipient right common iliac artery.
Positioning of the head of the pancreas graft cephalad
or caudad is not relevant with respect to successful
arterial revascularization. When pancreas transplanta-
tion is performed simultaneously with kidney transplan-
tation, the kidney is usually placed on the recipient
left iliac vessels. In some centers, ipsilateral placement
of the pancreas and kidney grafts is preferred.16 Both
organs may be transplanted through a midline incision
and placed intraperitoneally.8–10,16
Two choices are available for venous revasculari-
zation: systemic and portal. No clinically relevant dif-
ference in glycemic control has been documented
between the 2. Currently, approximately 15% of pan-
creas transplantations are performed with portal ve-
nous drainage and the remainder with systemic venous
drainage. Systemic venous revascularization commonly
involves the distal inferior vena cava, right common
iliac vein or right external iliac vein. If portal venous
drainage is used, dissecting out the superior mesen-
teric vein at the root of the mesentery is necessary.
The pancreas portal vein is anastomosed end-to-side
to a main tributary (usually the iliocolic vein) of the
superior mesenteric vein. We prefer to place the pan-
creas graft retroperitoneally behind the mesocolon of
the ascending colon because only a short arterial Y-graft
is needed for arterial anastomosis. If the pancreas graft
is placed intraperitoneally, the arterial Y-graft should
be long enough to be placed through a window in the
mesentery to reach the right common iliac artery for
arterial anastomosis. Portal venous drainage of the pan-
creas is more physiologic with respect to immediate
delivery of insulin to the recipient liver. This results in
diminished circulating insulin levels relative to those
in systemic venous-drained pancreas grafts.8–10,16
Markers for rejection include clinical signs and
symptoms of pancreas graft pancreatitis and measure-
ment of serum blood sugar, amylase or lipase levels
coupled with biopsy. Unfortunately, there is no ideal
marker to monitor rejection of the pancreas graft
because none of the clinical features and serum mark-
ers are good enough for early detection of pancreas
rejection. The pancreas is sometimes drained into the
bladder if a PTA or PAK transplantation is performed
in order to measure urinary amylase levels as a method
of detecting rejection.8–10,16
Pancreatic exocrine drainage is managed by means
of anastomosis of a duodenal segment to the bladder or
anastomosis to the small intestine. Currently, approxi-
mately 80% of pancreas transplantations are performed
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with enteric drainage; the remaining 20% are performed
with bladder drainage. The bladder-drained pancreas
transplantation is a very important modification intro-
duced in about 1985. By monitoring urine amylase
level, this technique significantly increases the imme-
diate success rate by easy and early detection of pan-
creas rejection and improves the safety of the procedure
by minimizing the occurrence of intra-abdominal ab-
scess from leakage of enteric-drained pancreas grafts.
However, bladder drainage may carry a risk of signifi-
cant long-term genitourinary tract complications such
as bladder infection, cystitis, urethritis, urethral injury,
balanitis, hematuria, metabolic acidosis, and reflux pan-
creatitis. Eventually, about 10–24% of bladder-drained
pancreas grafts are converted to enteric drainage.
With the successful application of the new immuno-
suppressants and reduction in the incidence of rejec-
tion, enteric drainage of the pancreas transplant has
enjoyed a successful rebirth. Enteric drainage of pan-
creas grafts is physiologic with respect to the delivery
of pancreatic juice into the intestine. Enteric drainage
of pancreas grafts can be constructed with or without
a Roux-en-Y.8,16
Immunosuppression Therapy
The principles of immunosuppressant therapy after
combined or solitary pancreas transplantation are com-
parable with those after other solid organ transplanta-
tion. There is no doubt that recent developments in
immunotherapeutics have played a critical role in trans-
forming pancreas transplantation from a high-risk to 
a routine treatment. In particular, 2 factors led to im-
provements in safety and efficacy: (1) the recognition
of the advantages of multimodal maintenance immu-
nosuppressive regimens; and (2) the incorporation of
modern maintenance agents. However, because of
the higher rejection rates in pancreas transplantation,
a more potent immunosuppressive regimen is manda-
tory. At the same time, the careful use of diabetogenic
drugs such as steroids and the calcineurin inhibitors 
is of particular importance. Today, quadruple therapy
is the standard immunosuppressive regimen after pan-
creas transplantation, consisting of an induction and
maintenance therapy. The necessity of an induction
therapy is most often related to a recipient’s high risk
of rejection episodes. Another reason to use induction
therapy is that it will provide a short course of potent
immunosuppression that permits immediate and even
permanent elimination of 1 or more of the mainte-
nance agents required post-transplant, such as corti-
costeroids. So far, no definitive agreement has been
reached with regard to what constitutes the single best
multimodal strategy.3,17 The following are common
immunosuppressants:
• T-cell immunosuppressants
– tacrolimus (FK506, Prograft)
– cyclosporine (Sandimmune, CyA or Neoral)
– daclizumab (Zenapex)
– basiliximab (Simulect)
– muromonab-CD3 (OKT3)
• B-cell immunosuppressants
– anti-thymocyte globulin (ATGAM)
– thymoglobulin (RATG)
• nonspecific immunosuppressants
– corticosteroids (methylprednisolone, predniso-
lone, hydrocortisone)
– mycophenolate mofetil (MMF, CellCept)
– azathioprine (Immuran, AZA)
Complications
Surgical complications are more common after pan-
creas transplantation than after kidney transplantation.
Nonimmunologic complications of pancreas trans-
plantation account for graft losses in 5–10% of cases.
These commonly occur within 6 months of transplan-
tation and are as important an etiology of pancreas
graft loss in SPK transplantation as acute rejection is.
Vascular thrombosis is a very early complication,
typically occurring within 48 hours and usually within
24 hours of transplantation. This is generally due to
venous thrombosis of the pancreas portal vein. The
etiology is not defined entirely but is believed to be
associated with reperfusion pancreatitis and the rela-
tively low-flow state of the pancreas graft. Prudent
selection of donor pancreas grafts, short cold ische-
mia times, and meticulous surgical technique are all
necessary to minimize graft thrombosis.
Transplant pancreatitis occurs to some degree in
all patients postoperatively. Temporary elevation in
serum amylase levels for 48–96 hours after transplan-
tation is common. These episodes are transient and
mild, without significant clinical consequence.
The most serious complication of the enteric-
drained pancreas transplantation is leak and intra-
abdominal abscess. This serious problem usually occurs
1–6 months after transplantation. Patients present with
fever, abdominal discomfort, and leukocytosis. A high
index of suspicion is required to make a swift and accu-
rate diagnosis. Percutaneous access of intra-abdominal
fluid collection for Gram stain and culture is essential.
The flora is typically mixed, with bacteria and often fun-
gus, particularly Candida. Broad-spectrum antibiosis
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is essential. Surgical exploration and repair of the
enteric leak is necessary. A decision must be made on
whether the infection can be eradicated without re-
moving the pancreas allograft. Peripancreatic infections
can result in development of a mycotic aneurysm at
the arterial anastomosis that could cause arterial rup-
ture. Transplant pancreatectomy is indicated if mycotic
aneurysm is diagnosed. Occurrence of intra-abdominal
abscess has been reduced greatly with increased recog-
nition of the criteria for suitable cadaveric pancreas
grafts for transplant. Improved perioperative antibio-
sis, including antifungal agents, has contributed to the
decreased incidence of intra-abdominal infection as
well. Perhaps the most significant contribution to re-
ducing the incidence of intra-abdominal abscess is the
efficacy of immunosuppressive agents in reducing the
incidence of acute rejection and thereby minimizing
the need for intensive immunotherapy.8–10,16
Gastrointestinal bleeding occurs in the enteric-
drained pancreas from a combination of perioperative
anticoagulation and bleeding from the suture line of
the duodenoenteric anastomosis. This is self-limiting
and will manifest as diminished hemoglobin level asso-
ciated with heme-positive or melanotic stool. Conser-
vative management will suffice.8–10,16
Effects of Pancreas Transplantation on
Diabetic Complications
Patients with a functioning pancreas graft describe their
quality of life and rate their health significantly more
favorably than those without. Satisfaction encompasses
not only physical capacities but also psychosocial and
vocational aspects.
A successful pancreas-kidney transplantation pre-
vents glomerular changes of kidney allografts in patients
with type 1DM. This has been observed in transplanted
kidneys of patients undergoing SPK transplantation,
as well as in kidneys of recipients undergoing PAK
transplantation. These studies provide evidence of the
efficacy of normalizing blood glucose and glycosylated
hemoglobin levels to prevent the progression of dia-
betic glomerulopathy in renal allografts. Furthermore,
successful pancreas transplantation will halt or reverse
the pathology in the native kidneys of patients with
type 1 DM and very early proteinuria.8–10,12,16
Motor-sensory and autonomic neuropathy was re-
ported to be halted and, in many cases, reversed 1–2
years after a successful pancreas transplantation. How-
ever, this raises the possibility that improvement of
diabetic neuropathy occurs, in part, because of improve-
ment in uremic neuropathy after a pancreas-kidney
transplantation. However, PTA in pre-uremic patients
has also been shown to result in improvement in dia-
betic neuropathy. Many patients express subjective
improvements in peripheral sensation 6–12 months
after pancreas transplantation.8–10,12,16
Pancreas transplantation does not show an imme-
diate dramatic beneficial effect on pre-established dia-
betic retinopathy. Retinopathy appears to progress for
at least 2 years following pancreas transplantation, but
it begins to stabilize in 3–4 years compared to diabetic
recipients of kidney transplantation only.8–10,12,16
Outcomes After Pancreas Transplantation
According to IPTR and UNOS, patient survival at 
1 year after deceased donor pancreas transplantation
was at least 95% in all categories and highest in PTA,
with 95% in SPK, 95% in PAK, and 98% in PTA, and
at least 88% in all categories at 3 years.3–6
Statistically and clinically, the outcome of kidney
transplantation is significantly superior in patients who
receive SPK transplant versus patients with type 1 DM
who receive kidney transplantation alone. Pancreas
graft survival rate at 1 year after deceased donor trans-
plantation was 85% for SPK transplantations; kidney
graft survival was at least 89%. For solitary pancreas
transplantations, pancreas graft survival rate at 1 year
was nearly equal: 78% for PAK and 76% for PTA. 
At 3 years, pancreas graft survival rates were at least
62% in all categories.3–6
Rejection rates at 1 year have steadily decreased
and are currently in the 10–20% range, depending on
case mix and immunosuppressive regimen. The 1-year
rates of immunologic graft loss have decreased to 2.6%
after SPK, 7% after PAK, and 9.7% after PTA.3
References
1. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC.
Allotransplantation of the pancreas and duodenum along with
the kidney in diabetic nephropathy. Surgery 1967;61:827–37.
2. Shyr YM, Su CH, Li AFY, Wu CW, Lui WY. Canine pancreas
allotransplantation with enteric drainage. J Chin Med Assoc 2002;
65:483–8.
3. Singh RP, Stratta RJ. Advances in immunosuppression for 
pancreas transplantation. Curr Opin Organ Transplant 2008;
13:79–84.
4. Gruessner AC, Sutherland DER. Pancreas transplant outcomes
for United States (US) and non-US cases as reported to the
United Network for Organ Sharing (UNOS) and the Interna-
tional Pancreas Transplant Registry (IPTR) as of June 2004.
Clin Transplant 2005;19:433–55.
5. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM,
Sung RS. Kidney and pancreas transplantation in the United
States, 1996–2005. Am J Transplant 2007;7:1359–75.
J Chin Med Assoc • January 2009 • Vol 72 • No 18
Y.M. Shyr
6. Patrick GD, Yogish CK, Mark DS. Long-term benefits of 
pancreas transplantation. Curr Opin Organ Transplant 2008;
13:85–90.
7. Meloche RM. Transplantation for the treatment of type 1 dia-
betes. World J Gastroenterol 2007;13:6347–55.
8. Sollinger HW, Geffner SR. Pancreas transplantation. Surg Clin
North Am 1994;74:1183–95.
9. Sollinger HW, Odorico JS, Knechtle SJ, D’Alessandro AM,
Kalayoglu M, Pirsch JD. Experience with 500 simultaneous
pancreas-kidney transplants. Ann Surg 1998;228:284–96.
10. Odorico JS, Young CJ, Sollinger HW. Pancreas transplantation.
Dig Surg 1994;11:420–7.
11. Hakim NS. Recent developments and future prospects in pan-
creatic transplantation. Exp Clin Transplant 2003;1:26–34.
12. Demartines N, Schiesser M, Clavien PA. An evidence-based
analysis of simultaneous pancreas-kidney and pancreas trans-
plantation alone. Am J Transplant 2005;5:2688–97.
13. Ryan EA, Bigam D, Shapiro AMJ. Current indications for 
pancreas or islet transplant. Diabetes Obes Metab 2006;8:1–7.
14. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman A,
Magee JC, Cibrik D, Wolfe RA, et al. The impact of simulta-
neous pancreas-kidney transplantation on long-term patient
survival. Transplantation 2001;71:82–90.
15. Humar A, Kandaswamy R, Granger D, Gruessner RW,
Gruessner AC, Sutherland DER. Decreased surgical risks of
pancreas transplantation in the modern era. Ann Surg 2000;
231:269–75.
16. Boggi U, Vistoli F, Chiaro MD, Signori S, Candio GD,
Amorese G, Coppelli A, et al. Surgical techniques for pancreas
transplantation. Curr Opin Organ Transplant 2005;10:155–68.
17. Schmied BM, Muller SA, Mehrabi A, Welsch T, Buchler MW,
Zeier M, Schmid TJ, et al. Immunosuppressive standards in
simultaneous kidney–pancreas transplantation. Clin Transplant
2006;20:44–50.
J Chin Med Assoc • January 2009 • Vol 72 • No 1 9
Pancreas transplantation
